Misplaced Pages

AVN-322

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
AVN-322
Names
IUPAC name 5-(benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetrazatricyclotrideca-1(9),3,5,7-tetraen-4-amine;hydrochloride
Other names List
  • 1194574-68-9
  • SB17475
  • 5-(Benzenesulfonyl)-N,11-dimethyl-2,3,7,11-tetraazatricyclo(7.4.0.0(2,6))trideca-1(9),3,5,7-tetraen-4-amine hydrochloride
  • starbld0039763
Properties
Chemical formula C17H20ClN5O2S
Molar mass 393.891 g/mol
Identifiers
CAS Number
ChemSpider
PubChem CID
UNII
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references
Chemical compound

AVN-322 is a 5-hydroxytryptamine subtype 6 receptor antagonist manufactured by Avineuro Pharmaceuticals Inc. that could potentially be used to combat Alzheimer's disease and schizophrenia. AVN-322 also reverses the negative effects of scopolamine and MK-80.

The compound is a sister drug to AVN-101 and AVN-211, two similar compounds under trial for treating Alzheimer's. Phase I trials for the drug were initiated in 2009 by Avineuro, and completed in the spring of 2010. The trials showed that AVN-322 was tolerated in a range of doses without any adverse effects, and Avineuro released plans to commence Phase II trials later the same year. The plan for further trials was discontinued in 2013.

References

  1. National Center for Biotechnology Information. "Compound Summary for CID 135905417, B7DM6S48B2" PubChem. Accessed 12 March 2023.
  2. "AVN-322 | CAS#1194574-68-9 | CAS#1194574-33-8 | 5-HT6 Antagonist | MedKoo". www.medkoo.com. Retrieved 2023-03-12.
  3. ^ Andrews, Megan; Tousi, Babak; Sabbagh, Marwan N. (2018-06-01). "5HT6 Antagonists in the Treatment of Alzheimer's Dementia: Current Progress". Neurology and Therapy. 7 (1): 51–58. doi:10.1007/s40120-018-0095-y. ISSN 2193-6536. PMC 5990506. PMID 29728891. S2CID 19186491.
  4. "Avineuro Announces Beginning Of Phase I Clinical Studies Of AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease". BioSpace. Archived from the original on 12 Mar 2023. Retrieved 2023-03-12.
  5. ^ "Avineuro Reports Positive Phase I Clinical Trial Results On AVN-322, Potent Small Molecule For Treatment Of Alzheimer's Disease". BioSpace. Archived from the original on 12 Mar 2023. Retrieved 2023-03-12.
  6. "Phase II trial of AVN 322 in patients with Alzheimer's disease. - AdisInsight". adisinsight.springer.com. Retrieved 2023-03-12.
Categories: